Supriya Lifescience Limited, a leading pharmaceutical company, has announced the appointment of Ms. Prachi Sathe as its Company Secretary and Compliance Officer, effective March 10, 2025. This decision was approved by the Board of Directors during a meeting held on the same day, following recommendations from the Nomination and Remuneration Committee.

This appointment underscores Supriya Lifescience's commitment to corporate governance and regulatory compliance. In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has formally disclosed this development to BSE Limited (BSE) and the National Stock Exchange of India Limited (NSE).

About Ms. Prachi Sathe

Ms. Prachi Sathe (ACS 70252) is a qualified Company Secretary and an Associate Member of the Institute of Company Secretaries of India (ICSI). She holds a postgraduate degree in law and a commerce degree from the University of Mumbai. With over 8 years of experience in secretarial and compliance functions, she brings a wealth of expertise in corporate governance, regulatory affairs, and compliance management.

Strategic Significance of the Appointment

The appointment of Ms. Prachi Sathe marks a significant step in Supriya Lifescience’s governance framework. Her expertise is expected to enhance regulatory adherence, corporate disclosures, and compliance efficiency. This move aligns with the company’s strategic focus on transparency, ethical governance, and compliance with SEBI regulations.

Board Meeting Highlights

• The Board of Directors convened on March 10, 2025, at 11:30 AM, and concluded the meeting at 12:00 noon.
• The appointment of Ms. Prachi Sathe was formally approved, reinforcing the company's commitment to strong corporate governance.
• The company confirmed that Ms. Sathe is not related to any director or key managerial personnel.

Commitment to Corporate Governance

With this appointment, Supriya Lifescience Limited continues to strengthen its corporate governance structure, ensuring adherence to best industry practices and regulatory frameworks. The company remains committed to maintaining the highest standards of compliance and enhancing stakeholder confidence.

This announcement further solidifies Supriya Lifescience’s dedication to regulatory excellence and corporate transparency, positioning the company for sustained growth and compliance leadership in the pharmaceutical industry.

The Upcoming IPOs in this week and coming weeks are Super Iron Foundry, Paradeep Parivahan.

The Current active IPO is PDP Shipping & Projects.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.